1. Scrip
  2. >>R&D
  3. >>Clinical Trials

An Early Surprise Win For BMS’s Opdivo/Yervoy In Lung Cancer

 
• By Mary Jo Laffler

CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.

Digital illustration of lung cancer cells in color background

Bristol-Myers Squibb Co. should be able to forestall some investor concerns about lagging sales of its one-time leading PD-1 inhibitor Opdivo when third quarter results are released on 31 October with the surprise announcement 22 October of an important win in the critical first-line lung cancer setting for the combination of Opdivo plus Bristol’s CTLA-4 inhibitor Yervoy and chemotherapy.

It’s an oddly similar dynamic to the previous quarter, when positive results from the Phase III CheckMate-227 trial came out the evening before second-quarter sales and earnings were released. The '227 data, which support the immuno-oncology combination’s use as a chemo-free option for first-line non-small cell lung cancer, dominated the earnings call – where Q2 Yervoy (ipilimumab) sales dropped from Q1, although they rose 17% from the second quarter of 2018 to $367m. Opdivo sales increased 12% year-over-year to $1.82bn for the second quarter of 2019

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from R&D

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.